ATE425971T1 - Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie - Google Patents
Ophthalmische zusammensetzungen zur behandlung der okularen hypertonieInfo
- Publication number
- ATE425971T1 ATE425971T1 AT04782695T AT04782695T ATE425971T1 AT E425971 T1 ATE425971 T1 AT E425971T1 AT 04782695 T AT04782695 T AT 04782695T AT 04782695 T AT04782695 T AT 04782695T AT E425971 T1 ATE425971 T1 AT E425971T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- occular
- hypertonia
- treating
- ophthalmic compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010020852 Hypertonia Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 229940125422 potassium channel blocker Drugs 0.000 abstract 1
- 239000003450 potassium channel blocker Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50009503P | 2003-09-04 | 2003-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE425971T1 true ATE425971T1 (de) | 2009-04-15 |
Family
ID=34312181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04782695T ATE425971T1 (de) | 2003-09-04 | 2004-08-31 | Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7410992B2 (de) |
| EP (1) | EP1663987B1 (de) |
| JP (1) | JP4546961B2 (de) |
| KR (1) | KR20060090801A (de) |
| CN (2) | CN1845904A (de) |
| AT (1) | ATE425971T1 (de) |
| AU (1) | AU2004272546B2 (de) |
| BR (1) | BRPI0414102A (de) |
| CA (1) | CA2537410C (de) |
| DE (1) | DE602004020079D1 (de) |
| EC (1) | ECSP066404A (de) |
| IL (1) | IL174068A0 (de) |
| IS (1) | IS8306A (de) |
| MA (1) | MA28017A1 (de) |
| MX (1) | MXPA06002515A (de) |
| NO (1) | NO20061505L (de) |
| NZ (1) | NZ545401A (de) |
| RU (1) | RU2006110625A (de) |
| WO (1) | WO2005026128A1 (de) |
| ZA (1) | ZA200601321B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2574078A1 (en) * | 2004-07-20 | 2006-02-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| JP5747392B2 (ja) * | 2010-03-26 | 2015-07-15 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物 |
| EP2626702A4 (de) * | 2010-10-08 | 2014-03-26 | Axis Inc | Diagnosemittel, diagnoseverfahren und therapeutisches mittel für fibromyalgie |
| US9487506B2 (en) | 2011-04-13 | 2016-11-08 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| CN110256314B (zh) * | 2019-06-28 | 2020-12-15 | 南京林业大学 | 一种β-芳基酮类化合物的制备方法及其产品 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2534580A1 (fr) * | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
| US5151444B1 (en) * | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| AU3693789A (en) | 1988-05-10 | 1989-11-29 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | New ophthalmic preparation for treating glaucoma |
| ES2317964T5 (es) * | 1988-09-06 | 2015-02-20 | Pfizer Health Ab | Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| CA2164733A1 (en) | 1993-06-08 | 1994-12-22 | Nino Sorgente | Methods and compositions for lowering intraocular pressure |
| US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5573758A (en) | 1995-04-28 | 1996-11-12 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| US5925342A (en) * | 1996-11-13 | 1999-07-20 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| EP1114816A4 (de) | 1998-09-14 | 2002-09-04 | Ono Pharmaceutical Co | $g(v)-SUBSTITUIERTE PHENYL-PROSTAGLANDIN-E-DERIVATE UND SIE ALS AKTIVEN BESTANDTEIL ENTHALTENDE MEDIKAMENTE |
| DE19846514A1 (de) * | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| EA005293B1 (ru) | 1999-12-22 | 2004-12-30 | Пфайзер Продактс Инк. | Производные пирролидин-2-она и их применение при лечении остеопороза |
| EP1251862B1 (de) * | 2000-01-18 | 2008-10-01 | Merck & Co., Inc. | Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension |
| PL358481A1 (en) | 2000-03-17 | 2004-08-09 | Alcon Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
| WO2001072268A1 (en) | 2000-03-31 | 2001-10-04 | Toray Industries, Inc. | Hair growth or hair formation controlling agents |
| WO2002024647A1 (en) | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| EA200300379A1 (ru) | 2000-11-27 | 2003-08-28 | Пфайзер Продактс Инк. | Селективные агонисты рецептора ep4 в лечении остеопороза |
| WO2003105847A1 (en) * | 2002-06-14 | 2003-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| EP1581503A4 (de) * | 2002-11-08 | 2007-07-25 | Merck & Co Inc | Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie |
| US7196082B2 (en) * | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| WO2005025568A1 (en) * | 2003-09-04 | 2005-03-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
-
2004
- 2004-08-31 AU AU2004272546A patent/AU2004272546B2/en not_active Ceased
- 2004-08-31 CN CNA2004800253442A patent/CN1845904A/zh active Pending
- 2004-08-31 CA CA002537410A patent/CA2537410C/en not_active Expired - Fee Related
- 2004-08-31 WO PCT/US2004/028266 patent/WO2005026128A1/en not_active Ceased
- 2004-08-31 BR BRPI0414102-4A patent/BRPI0414102A/pt not_active IP Right Cessation
- 2004-08-31 JP JP2006525389A patent/JP4546961B2/ja not_active Expired - Fee Related
- 2004-08-31 RU RU2006110625/04A patent/RU2006110625A/ru not_active Application Discontinuation
- 2004-08-31 CN CN201110399520.0A patent/CN102558231B/zh not_active Expired - Fee Related
- 2004-08-31 NZ NZ545401A patent/NZ545401A/en unknown
- 2004-08-31 AT AT04782695T patent/ATE425971T1/de not_active IP Right Cessation
- 2004-08-31 US US10/569,921 patent/US7410992B2/en not_active Expired - Lifetime
- 2004-08-31 MX MXPA06002515A patent/MXPA06002515A/es not_active Application Discontinuation
- 2004-08-31 EP EP04782695A patent/EP1663987B1/de not_active Expired - Lifetime
- 2004-08-31 KR KR1020067004459A patent/KR20060090801A/ko not_active Ceased
- 2004-08-31 DE DE602004020079T patent/DE602004020079D1/de not_active Expired - Lifetime
-
2006
- 2006-02-14 ZA ZA200601321A patent/ZA200601321B/xx unknown
- 2006-02-16 IS IS8306A patent/IS8306A/is unknown
- 2006-03-01 MA MA28846A patent/MA28017A1/fr unknown
- 2006-03-01 EC EC2006006404A patent/ECSP066404A/es unknown
- 2006-03-02 IL IL174068A patent/IL174068A0/en unknown
- 2006-04-03 NO NO20061505A patent/NO20061505L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200601321B (en) | 2007-05-30 |
| IS8306A (is) | 2006-02-16 |
| CN102558231A (zh) | 2012-07-11 |
| EP1663987A1 (de) | 2006-06-07 |
| DE602004020079D1 (de) | 2009-04-30 |
| NZ545401A (en) | 2008-10-31 |
| AU2004272546A1 (en) | 2005-03-24 |
| CA2537410A1 (en) | 2005-03-24 |
| BRPI0414102A (pt) | 2006-10-31 |
| JP2007504233A (ja) | 2007-03-01 |
| US20070010491A1 (en) | 2007-01-11 |
| CN1845904A (zh) | 2006-10-11 |
| US7410992B2 (en) | 2008-08-12 |
| KR20060090801A (ko) | 2006-08-16 |
| MA28017A1 (fr) | 2006-07-03 |
| RU2006110625A (ru) | 2006-08-10 |
| EP1663987B1 (de) | 2009-03-18 |
| CA2537410C (en) | 2009-08-11 |
| CN102558231B (zh) | 2015-05-27 |
| AU2004272546B2 (en) | 2007-10-18 |
| WO2005026128A1 (en) | 2005-03-24 |
| MXPA06002515A (es) | 2006-06-20 |
| ECSP066404A (es) | 2006-09-18 |
| IL174068A0 (en) | 2006-08-01 |
| JP4546961B2 (ja) | 2010-09-22 |
| NO20061505L (no) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60307607D1 (de) | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten | |
| DE60220422D1 (de) | Substituierte pyrazoloverbindungen zur behandlung von entzündungen | |
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| WO2005002520A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| EA200700099A1 (ru) | Производные пиридина | |
| TW200740760A (en) | Malonamide derivatives | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
| BRPI0411673A (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
| TW200501949A (en) | Ophthalmic compositions for treating ocular hypertension | |
| SE0402925D0 (sv) | Novel Compounds | |
| WO2005020917A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| WO2006044425A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| WO2004043354A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| DE602004021358D1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| DE60003435D1 (de) | Neue 2-decarboxy-2-phosphinico prostaglandin f analoge | |
| ATE425971T1 (de) | Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie | |
| DE60135972D1 (de) | Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension | |
| CA2534634A1 (en) | Azolidinecarbonitriles and their use as dpp-iv inhibitors | |
| PH12022551012A1 (en) | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease | |
| WO2006020003A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| SG146685A1 (en) | Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| WO2008030390A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| DE60005525D1 (de) | 2-aminotetraline zur behandlung von glaukom | |
| TW200509889A (en) | Aniline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |